ReviewDer Internist2009
[Obstructive pulmonary diseases and pulmonary hypertension].
Review in Der Internist, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension is a frequent complication of chronic obstructive pulmonary disease. Especially in patients with concurrent sleep apnoe syndrome (so called "overlap syndrome"), the risk for pulmonary hypertension is high. Pathophysiologically, both toxic effects (cigarette smoke) and alveolar hypoventilation can induce dysfunction of the pulmonary endothelium. Genetic factors and cytokines/growth factors released by inflammatory cells may induce remodeling of the pulmonary vessels. Pulmonary hypertension results, which is initially reversible, but gradually worsens over time. At present, therapeutic options include long term oxygen in addition to the treatment of the underlying disease. A subgroup of patients may profit of a specific therapy with sildenafil and other new substances. However, studies that define these subgroups need to be performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.